Heron Therapeutics, Inc. (HRTX) Earnings Call Transcript & Summary

February 28, 2022

NASDAQ US Health Care Biotechnology earnings 51 min

Earnings Call Speaker Segments

David Szekeres

executive
#1

Thank you, Morena. Good afternoon to all of you, and we appreciate your participation today. Joining me from Heron are Barry Quart, who serves as Chief Executive Officer and Chairman; John Poyhonen, our President and Chief Commercial Officer; Kimberly Manhard, Executive Vice President of Drug Development and a Board Director; and Chris Storgard, our Chief medical Officer. If you're listening through the conference call, the slides are being provided through webcast and may likewise be reached by visiting the Investor Relations section of our site once today's call wraps up. Prior to starting, please let me note that forward-looking statements regarding Heron's future expectations, plans, prospects, corporate strategy and performance will be included in this call, and these constitute forward-looking statements for the purposes of the safe harbor provision under the Private Securities Litigation Reform Act of 1995. Various important factors, including those covered in our filings with the SEC, could cause actual results to differ materially from those these forward-looking statements indicate. Furthermore, any forward-looking statements reflect our views only as of the date of this webcast and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligations to update such statements. Now, I'll turn the call over to Barry.

Barry Quart

executive
#2

Thanks, David. Hello, everyone, and I appreciate your participation today. 2021 stood out as a hugely significant and highly productive period for this company. We secured initial clearance and brought ZYNRELEF to market successfully in the U.S. for treating postoperative pain, and merely 5 months following that launch, we gained authorization for a considerably broader indication statement, which substantially strengthens our capacity to commercialize this product. Through our CINV franchise, we steadied revenue within a market that is mostly generic and perceive an opportunity for modest expansion going forward. Additionally, we submitted an NDA for HTX-019, our fourth commercial product, aimed at postoperative nausea and vomiting, or PONV, which could potentially become many times bigger than our CINV operation. Finally, we directed our efforts toward reducing expenses — for instance, by giving up over 50% of our leased office space — and partnering ex-U.S. territories for ZYNRELEF, in order to lengthen our cash runway. As we disclosed in December, and in just a bit more than 2 months after submission, the FDA cleared the first of two planned supplemental NDAs to broaden the indication statement for ZYNRELEF so it covers roughly 7 million procedures, versus just about 2 million under the original label. The initial supplemental NDA that the FDA approved in mid-December widened the label to encompass foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures. The FDA likewise consented to the contents of the second supplemental NDA, which would broadly cover orthopedic and soft tissue surgical procedures. The status of the FDA-agreed studies for this second supplemental NDA appears on slide 5. Pharmacokinetics and safety serve as the endpoint in these studies. Showing efficacy is not necessary for approval; we anticipate submitting sNDA number two late in the second half of this year. Clearance of sNDA number two ought to broaden the label to cover essentially all 14 million target procedures; alongside sNDA 1, the FDA also granted approval for our manufacturing supplements covering a secondary supplier of our proprietary polymer and substantial increases in batch size for both ZYNRELEF and CINVANTI. Such approvals matter greatly in enabling us to produce adequate volumes of these vital products at a notably reduced cost of goods. On the whole, the fourth quarter and 2021 overall proved exceptional for Heron. I'll now hand the call to John so he can go over how we achieved key commercial and corporate milestones during 2021.

John Poyhonen

executive
#3

Thanks, Barry. I'm glad to be here to discuss what we achieved commercially in Q4; as we continue introducing ZYNRELEF, we're seeing substantial progress. During my comments, I'll start with a handful of updates regarding important metrics. In addition, I'll expand our disclosure by adding fresh figures related to ZYNRELEF demand unit volume involving hospitals and ASC; following that, I'll close with a report on the commercial performance of our oncology care business. Turning to slide 7, I'll recap the launch milestones for ZYNRELEF up to this point. This launch's initial two quarters proved challenging, because the original FDA label indication covered only three particular procedures, and COVID-19's ongoing impact added further pressure. Even so, we've achieved remarkable progress on several leading indicators, and that gives us confidence ZYNRELEF will ultimately become the leader in the postoperative pain market; we keep securing formulary approvals for ZYNRELEF among targeted hospitals and IDNs at a fast pace; that stands as our growth pipeline. The growth in unique ordering accounts pleases us greatly, and just as important, reorder rates are growing excellently as well; beyond that, we're witnessing substantial growth in ZYNRELEF demand unit volume on both a quarterly and a monthly basis. I'll provide the specifics behind each of these metrics later on. During our December update, we mentioned that our R&D group worked alongside the FDA to obtain a significant expansion of the label for ZYNRELEF's approved indications, and this was accomplished faster than anyone expected. The addressable patient population has grown from approximately 2 million surgical procedures to roughly 7 million surgical procedures. We are seeing an early benefit from this wider indication already, reflected in increased ZYNRELEF adoption by the same surgeons who had been using the product before. Just as we expected, initial stocking inventory remained in the distribution channel when the third quarter came to a close. Since then, we have made considerable headway in reducing those inventory levels, fueled by stronger unit volume sales of ZYNRELEF. Finally, I want to recognize our team for doing an outstanding job expanding separate reimbursement for ZYNRELEF beyond the surgical bundle. With that, let's get into the specifics. Slide number 8 shows how quickly ZYNRELEF is securing formulary approvals. At October's end, we reported 126 formulary approvals. That figure has more than doubled, reaching 260 formulary approvals as of February 25th. Our successful formularies look even stronger given the many delays caused by COVID. And among those accounts actually making P&T decisions, more than 90% of hospital P&T committees are adding ZYNRELEF to formulary. Importantly, more than 60% of our formulary approvals permit unrestricted usage of ZYNRELEF. Those unrestricted formulary approvals open a significant growth opportunity now that the broader label was approved by the FDA in mid-December. What keeps driving things are the better clinical results ZYNRELEF delivers relative to bupivacaine, the current standard of care — specifically 72 hours of pain relief plus a meaningful drop in opioid consumption. Combine the strongest product available with ZYNRELEF's terrific value story, which rests on how we've priced it and the headway we're making on reimbursement, and those points land clearly with the accounts we're targeting. Q1's remaining stretch will be nonstop, because over 100 additional P&T committees are scheduled to review ZYNRELEF before the quarter wraps up. New formulary approvals help us lay the groundwork for future ZYNRELEF revenue, and that effort remains front and center for our commercial organization. Next, I'd like to highlight one of our main top-down approaches: focusing on integrated delivery networks, or IDNs, so we can unlock new system-wide opportunities for therapeutic interchange from Exparel to ZYNRELEF in the procedures where it's indicated. So far, ZYNRELEF has been added to the formularies of 34 IDNs. Across those IDN systems, there are close to 270 institutions in their networks, and 41% of the approvals allow unrestricted use of ZYNRELEF. On top of that, those 34 IDNs account for an estimated 520,000 procedures per year for which ZYNRELEF is indicated, as well as $61 million in Exparel sales. What we've accomplished with IDNs enables us to work with senior-level decision makers, who are evaluating a move from Exparel to ZYNRELEF for indicated procedures. The rationale behind a potential switch is simple: when measured against bupivacaine, the usual standard of care, ZYNRELEF has delivered better clinical outcomes. On top of that, it brings cost reductions—25% to 32% when calculated using wholesale acquisition cost, and 42% to 48% under our 340B price offering—when compared with EXPAREL. Because ZYNRELEF now carries a broader label indication, it makes sense that IDNs want to capture millions in savings from a therapy that genuinely provides relief for as long as 72 hours; on slide 10, Symphony Health data was used to benchmark how many distinct ordering accounts appeared across the initial half-year following launch; during that same initial six-month window, ZYNRELEF has been building real momentum, reaching 309 distinct ordering accounts, compared with 160 such accounts seen in the first three months after launch. Three non-opioid analgesics — ZYNRELEF, Xaracoll and Anjeso — have all reached the market over the last two years, a period shaped by COVID. When it comes to the count of distinct accounts placing orders, ZYNRELEF exceeds Anjeso, its nearest rival, by more than fourfold. On top of that, 73% of those accounts placed repeat orders within the opening six months — no other product among the four examined in this benchmark analysis achieved a higher reorder rate. In our view, that speaks volumes about how well surgeons are seeing the product perform with their patients in actual practice. We also consider these early ZYNRELEF figures to be excellent, particularly since the label covered just three procedures when we launched and the COVID surge disrupted hospital rollouts. Even though ZYNRELEF is off to a solid start, one of our main goals for ‘22 is growing the count of accounts placing orders at a rapid pace, and we continue to see meaningful momentum, which the first quarter made clear. On slide 11, you can see how we've kept adding to the total of distinct accounts that have ordered, and we're disclosing ZYNRELEF demand unit volume here for the first time. At the close of December 2021, that figure stood at 309, and by the end of last week it had climbed past 400. ZYNRELEF's demand unit volume increased 126% in Q4 versus Q3. With that said, we should recognize that the Omicron surge slowed ZYNRELEF's growth in December and January. During those two months, our customers were affected by elective procedure postponements stemming from policy decisions, individuals receiving positive pre-op COVID test results, and workforce shortages. This unexpected surge certainly undermined the positive progress we experienced in mid-December—which Barry discussed earlier—when ZYNRELEF's label indication was expanded to cover approximately 7 million surgical procedures. Fortunately, it appears the Omicron variant wave has passed, and February saw a substantial increase in ZYNRELEF demand volume, rising 42% compared to January's figures even with 3 fewer days. Significantly, since the start of our launch, 77% of demand SKU volume has been allocated to our 400-milligram product, which carries a price nearly twice that of our 200 milligram SKU. We think that widely expanding ZYNRELEF's label indication, together with COVID's impact leveling off, positions us for a solid close to Q1 and for how the rest of 2022 plays out. On the earlier slide, I covered ZYNRELEF's substantial demand unit volume growth on a quarterly basis as well as a monthly one.

John Poyhonen

executive
#4

Our view is that expanded indications are driving a big share of this increase. To back that up, in mid-January we ran a pulse survey involving 129 orthopedic surgeons who had previously used ZYNRELEF and performed TKA procedures. More than 99% of the surgeons we surveyed continued to use ZYNRELEF with their patients. After that, we asked whether they had used ZYNRELEF in total hip replacement cases; before the label expansion in mid-December, just 29% of surgeons said they had used it and THA. Within the one month following the FDA's approval of the expanded indication, that figure rose to 48% of surgeons using ZYNRELEF and THA. Notably, 91% of those who haven't yet tried ZYNRELEF and THA cases intend to use it within the next one to three months. It's worth noting that THA procedures total more than 600,000 each year. So this is a great example of how our expanded indication will let us speed up ZYNRELEF's growth. Among the questions we get most often is about how much inventory sits in the distribution channel. As anticipated, the third quarter closed with excess initial stocking inventory and the distribution channel. Since then, we've made substantial progress burning through that inventory, driven by increases in ZYNRELEF demand unit volume sales. Fourth quarter net sales came to $844,000 as we drew down the initial stocking inventory, based on demand orders from hospitals and ASCs; we currently have 85 distribution centers, which are selling ZYNRELEF. To give a better read on inventory level and the distribution channel, we're reporting ex-factory reorder rate based on demand units for both SKUs. In the end, our aim is for ex-factory orders to reach 100% of demand unit volume, which means a distribution channel is replenishing its inventory for every unit sold to a hospital or ASC. Through February 24th, we've made excellent progress toward this goal, with the 400-milligram SKU reorder rate at 96% of demand unit volume; we expect to hit that 100% reorder rate target by the end of the first quarter. As for the 200 milligram SKU, the reorder rate currently stands at 40%, which indicates there's some excess 200 milligram inventory in the distribution channel. That isn't surprising given the 200 milligram SKU accounts for 23% of the total ZYNRELEF demand unit volume. We've already seen significant gains in the 200 milligram ex-factory reorder rate during the first quarter, and expect further improvements through the rest of the first quarter based on the new indicated procedures utilizing 200 milligram doses. We've already seen tremendous early results on reimbursement coverage from commercial and Medicaid payers. We've already secured separate reimbursement outside the surgical bundle payment for ZYNRELEF in more than 120 million covered lives in ASCs. And in some cases, it's also separately reimbursed in the hospital outpatient setting. One crucial element of how we set prices is that, even when there's no separate reimbursement, our reduced acquisition costs help patients in every setting of care where the drug might be covered under the surgical bundle payment. During the fourth quarter, CMS granted ZYNRELEF a dedicated C-code, C9088, allowing separate reimbursement in the ASC setting of care, starting January 1, 2022. That's going to matter a great deal for ZYNRELEF, because it means separate reimbursement outside the surgical bundle in the ASC market, extending past the usual three-year pass-through window. Our pass-through application is still under review by CMS, and we anticipate pass-through for separate reimbursement of ZYNRELEF for Medicare patients in the hospital outpatient setting of care to take effect April 1, 2022. That would represent a major competitive edge, given that Exparel's pass-through status in the hospital outpatient setting of care lapsed years ago. Moving to slide 15, I'll wrap up the ZYNRELEF portion with our main priorities for 2022. Number one is capitalizing on the new indication to drive even faster growth. We'll do that by growing existing surgeon usage as well as new procedures. This aligns with the example I gave earlier — orthopedic surgeons expanding beyond TKA cases alone to also include THA patients. Beyond that, we're partnering with accounts that already have ZYNRELEF formulary approval to lift restrictions and permit use across all of our newly indicated surgical procedures. And lastly, we're starting to build momentum with both IDNs and hospitals around revisiting therapeutic interchange — switching Exparel to ZYNRELEF for indicated procedures, which could potentially save millions of dollars per year. Priority number two is boosting usage within ordering accounts by growing the number of surgeons who routinely use ZYNRELEF. A lot of ordering accounts first evaluated ZYNRELEF with two or three surgeons from a larger practice. Given the excellent outcomes their patients experienced, we're actively drawing on that experience to support expanded usage of ZYNRELEF with recounts; this approach is gaining momentum for increasing usage. Priority number three is to keep securing formulary approvals at new targeted IDNs and hospitals. Greater access is our pipeline for growth and lets our sales reps expand our volume, once other accounts are in service and converted to ZYNRELEF. And finally, we'll keep maximizing our separate reimbursement outside of the surgical bundle payment for ZYNRELEF in the ASC setting of care. We remain optimistic about receiving pass-through status for ZYNRELEF for Medicare patients, with the hospital outpatient setting of care effective April 1st. To sum up, we've achieved incredible progress on a number of leading indicators, which gives us confidence that 2022 will be a year of significant growth for ZYNRELEF; now I'd like to shift gears and go over the fourth quarter results of our oncology care franchise. On slide 17, the fourth quarter was another solid performance for CINV franchise products, with net sales of $19.9 million. The marketplace continued to face major challenges, as COVID-19 reduced cancer screenings and new patient starts; beyond that, CMS's oncology care model and other value-based contracts encourage community oncology practices to shift toward lower-cost generic and biosimilar options. Lastly, competing products kept up strong value or net cost recovery for oncology practices through aggressive pricing. We think several of these challenges will start to reverse in 2022; on slide 18, throughout 2021, our team did a great job steadying sales in our CINV portfolio and in markets where generic competition dominates. To be more specific, we largely held CINVANTI demand unit sales steady at 98% of 2020 levels; we also began the work of growing SUSTOL after the Refresh Program we launched in 2019; we believe our products are set for moderate growth in 2022. Our view that CINVANTI and SUSTOL are both set for moderate growth in 2022 rests on two key factors. First, we'll see improving reimbursement tailwinds because generic fosaprepitant average sales price reimbursement fell to $28.50 in Q1 2022, and as of January 1st, separate reimbursement in the hospital outpatient segment came to an end, which will make CINVANTI's value proposition far more appealing in 2022. Also, IV Akynzeo ASP reimbursement dropped by more than $190 over the past year; so there's less value they can provide, which benefits both SUSTOL and CINVANTI. For the first quarter of 2022, we anticipate our CINV net product sales will fall in the range of $20 million to $22 million.

John Poyhonen

executive
#5

One possible positive factor is the shortage of IV bags that a number of accounts are running into, and that works in CINVANTI's favor since it's the sole NK-1 that requires no IV infusion bag. On top of that, COVID has left us with a backlog of oncology patients. We also think HEC and most MEC regimens are settings where both products can be used. When new patients come back into the system seeking treatment, those patients will open up growth potential for both of our products. Last, I'd like to wrap up with a look at Heron's commercial strategy. That strategy has two main pieces. The first is making Heron a leading acute care company. As I said before, ZYNRELEF has plainly gotten off to a quick start, even with headwinds, and it's expanding fast. Barry already went over our arrangement with the FDA to broaden our label indications, and that will speed up ZYNRELEF's growth down the road. Last, we're in a fortunate spot to potentially bring on a second commercial product, HTX-019 for PONV, in the fourth quarter of 2022; with the same commercial team and customer targets, that product will let us optimize our acute care resources. The second piece of our commercial strategy is returning growth and maximizing the profitability of the oncology care business. We've stabilized sales in a competitive generic market and are set for moderate growth in 2022; beyond that, we've taken key steps to maximize profitability of oncology care products. The first step is investing in larger scale manufacturing for CINVANTI, which will bring COGS down significantly in 2022. We've also better aligned our resources to support maximizing profitability through significant cost reductions and expense savings. That wraps up my prepared remarks, and I'll now hand the call back to Barry.

Barry Quart

executive
#6

Thanks, John. Now I'd like to spend a few minutes talking about the NDA we have pending for HTX-019. For Heron, postoperative nausea and vomiting represents a sizable and significant new market, yet it fits perfectly alongside what we're already doing commercially in postoperative pain, and it extends the deep expertise we've built around nausea and vomiting. When you look at PONV, that opportunity comes in at roughly 25 times what CINV represents, and HTX-019 brings meaningful benefits relative to the products out there today. Our filing has been accepted by the FDA, which handed us a PDUFA action date of September 17, 2022. That means a potential launch of HTX-019 during the fourth quarter of 2022, with the chance for several hundred million dollars in sales at peak. One straightforward early commercialization target is converting more than 500,000 oral aprepitant pills that are forecast to be sold in 2022 for PONV. How oral aprepitant has grown for PONV makes a persuasive case for what HTX-019, an easy-to-use IV form of aprepitant, can do. Despite having no promotion behind it and facing considerable constraints from the oral route along with a high acquisition cost, oral aprepitant has posted solid growth across the last few years, which included 25% growth last year. Once we have approval, we intend to pursue those units aggressively. During today's call, you've already heard the commercial figures from each of our product franchises. To close things out on our financials, though, let me move through those numbers quickly and add a bit more color on our overall financial picture. Net product sales in the fourth quarter of 2021 across both commercial franchises came to $20.7 million, versus $20.6 million during the same period in 2020. On ZYNRELEF, net product sales for the fourth quarter of 2021 totaled $0.8 million, with ZYNRELEF demand units up 126% compared with the prior quarter; CINVANTI net product sales reached $17.4 million for the fourth quarter, versus $20.3 million during the same period in 2020; SUSTOL product sales came in at $2.5 million for the fourth quarter of 2021, versus $0.3 million during the same period in 2020; and in the first quarter of 2022, we anticipate net product sales for the oncology care franchise landing somewhere between $20 million and $22 million. As of December 31, 2021, cash, cash equivalents and short-term investments stood at $157.6 million. Turning to our operations, net cash used for operating activities for the year ended December 31, 2021 was $203.4 million, versus $184.8 million during the same period in 2020. That rise in net cash used for operating activities stemmed mainly from working capital changes tied to the July 2021 launch of ZYNRELEF, including manufacturing of commercial inventory. For the first quarter of 2022, we expect net cash used for operating activities between $44 million and $48 million, which includes 8.5 annual expenses that don't reoccur in subsequent quarters. For 2022, we expect the amount of cash we burn to come down, driven by growth in net product sales and the payoff from steps we've taken to save costs. Those steps include lower spending within the oncology care franchise, less spent on leases, and a smaller investment in manufacturing, since the key enhancements have now received FDA approval. We also expect lower COGS thanks to greater manufacturing scale for ZYNRELEF as well as CINVANTI. On slides 25 and 26, you'll find critical safety information regarding ZYNRELEF. Those slides can be accessed on our website. Having said that, we're ready to take your questions. Operator?

Brandon Folkes

analyst
#7

Hi there. I appreciate you fielding my questions. I've got two, I think. Could you expand a bit on how the removal works for that usage limitation that might have been put in place prior to the labels being broadened? So perhaps certain approvals you received before broadening, purely so you could reach 100%, or perhaps near that, of formulary approvals that align with the label — any detail on the expected duration, how you'd characterize that process, and when the revenue pull-through will show up? Then, Barry, I value what you said at the close regarding cash and capital, any additional thoughts or opportunities past those you brought up to potentially demonstrate after a longer timeline? Thanks a lot.

Barry Quart

executive
#8

Of course. Thanks, Brandon. I appreciate that. John, could you please address the inquiry about pull-through from the broadened label and the formularies?

John Poyhonen

executive
#9

Yeah, definitely. So like I mentioned during the presentation, we're at 260 formulary approvals as of the close of last week, February 25th, and 65% of those are unrestricted usage. So in those accounts, Brandon, we can already really promote for the full label that we have. The remaining 35%, I think, are the accounts where — as you said, we have a restricted label. And we're working with those accounts. We've begun working with them to grow the ability to use ZYNRELEF. And I'd say that, right now, based on the feedback I've seen, roughly 50% of those accounts have expanded to unrestricted usage. So we're seeing very good results on that. The others are in process. And I would hope, probably by the end of April, that we'll be in a position where the vast majority of accounts would allow for unrestricted usage of ZYNRELEF, based on our new broader label.

Barry Quart

executive
#10

Thanks. And yes, when it comes to our cash situation, our attention is squarely on lengthening the runway and ensuring we reach profitability. We're examining not just the possibility of partnership deals — there's substantial interest in partnering a product across multiple regions — but also many other avenues. We won't elaborate further at this point, though you should expect action aimed at strengthening the balance sheet shortly.

Brandon Folkes

analyst
#11

I appreciate that a lot.

David Szekeres

executive
#12

Then David Szekeres said: Boris? Operator, could you move on to the following caller, and afterward we'll return to Boris?

Josh Schimmer

analyst
#13

Thanks for fielding these. You gave us plenty of positive color regarding the ZYNRELEF rollout, yet when all is said and done, the figures that came in were pretty tiny. A threefold increase would still leave them on the small side. So could you perhaps sharpen our focus on what kind of step functions in demand we should expect and when, whether via the IDNs or some other channel, that would shift ZYNRELEF onto a stronger path? That's my first item. Second, with the financing overhang in play, can the CIN franchise be monetized somehow? If that's possible, could you split out 019 from it? And finally, will you be reporting as a going concern in your 10-K?

Barry Quart

executive
#14

Let me take that last one. No, after a careful look at our finances and given the expense cuts, a few of which I mentioned, we don't need to flag a going concern issue. John, would you like to address the trajectory?

John Poyhonen

executive
#15

Yeah, absolutely. So Josh, I believe this marks the first occasion where we've shown you what those demand units actually look like. And obviously, the growth you're seeing is quite robust. Sadly, just as we were preparing to significantly speed up that growth, the Omicron surge arrived, and that hurt us on two fronts — December and January sales — right around when the FDA expansion came through. So we had anticipated some very substantial growth in that area. What we're observing now is that from January to February, with a 42% jump and three days remaining, things are beginning to accelerate at a pace we feel good about. The critical areas of focus, I'd say, will involve examining those priorities, ensuring we broaden usage among the product's existing applications, and also trying to bring in additional surgeons at the same practice. Still, your observation regarding therapeutic interchange is a strong one. We're already in discussions with several accounts capable of shifting millions of dollars in additional business over to ZYNRELEF quite rapidly. Those furthest along are already running trials inside their own institutions, which would let them make that pivot to ZYNRELEF very swiftly. That said, pinning down the timing is somewhat difficult. As you can probably guess, one of our biggest hurdles has been that this is such a fluid period, and forecasting that ramp-up rate is tough — particularly since we're only now witnessing the biggest growth between January and February; so we've got just one data point; but we'll keep monitoring it very carefully; and my hope is that in the coming quarter or thereabouts, we'll be able to offer more guidance regarding which way the growth rate for ZYNRELEF is heading.

Josh Schimmer

analyst
#16

Then, when it comes to generating revenue from the CINV franchise?

Barry Quart

executive
#17

Yeah, for sure. Clearly, that is one area we're looking into quite thoroughly and we've had meaningful conversations about it. And yes, HTX-019 could be carved out; that's actually a fairly simple opportunity that's also come up in discussions. So, like I mentioned, our aim is to clear up this financial overhang in the reasonably near future. And that definitely is among the choices available to us.

Serge Belanger

analyst
#18

Hello there. Good afternoon, everyone. I have a handful of things I'd like to ask about Exparel. To start, regarding inventory, you said a substantial portion of the initial channel stock has already been used up. I'm just wondering what the situation looks like at present, and when it will get back to normal and match the product's demand. Second, could you share some sense of the typical price for one unit, so that we're able to roughly work out what the present revenue run rates are, using the demand units? And third, the final one, I believe this is for Barry. As I recall, previously your unofficial guidance concerning ZYNRELEF was that it would surpass Exparel's sales across the first six quarters following launch, so I'm just wondering where things stand on that, given that we're one-third of the way through. Thanks.

Barry Quart

executive
#19

Yes, absolutely. Thank you, Serge. The first question I'll hand to John. Let me simply note that he pointed out we are basically at the neutral point when it comes to inventory for the 400-milligram vials. So, given that practically every one of the distribution centers is reordering and we are quite near that, definitely by the time the quarter ends, we expect to reach a state where usage and ordering ought to be roughly one for the 400, while 200 lags somewhat. Because of the three specific indications, 200 represents a lesser share of total use during the product's original launch. Now, as the indications have expanded, there are far more indications for which the 200-milligram vial is suitable. Thus we anticipate that it will begin climbing and start working through that inventory across the next quarter. John, anything else you'd like to add?

John Poyhonen

executive
#20

Absolutely, Barry — I believe you captured that quite accurately, and I'm fully on board with the idea that when looking at it from a 400 perspective, a single unit of demand will correspond to one reorder, meaning that piece is already in normalized territory. Regarding what we've observed with the 200-milligram SKU, Serge, if you examine our position back in January — 388 units versus 761 — it's clear the 200-milligram SKU is expanding at a faster pace. And although as of the close of last week we're sitting at a 40% reorder rate, we anticipate making quite meaningful headway on that from now through the quarter's end. So my sense is we'll come near it. Whether we land exactly there, I can't say for certain, but my expectation would be something above 80% for the reorder rate as we move ahead toward the conclusion of the quarter. Thus, by the time we reach the end of this quarter, you should begin to see figures that better capture genuine demand along with net sales derived from ex-factory sales.

Barry Quart

executive
#21

Yes, and regarding the second question. Look, the way we view the launch, as John said, we've achieved really substantial success with formularies in getting into facilities. But with COVID and with the very limited label at the start, it's truly been a major hindrance when it comes to uptake in those facilities; so, in a way, we actually see the start of this year as a relaunch of the product, with a significantly expanded label now that COVID is beginning to wane in terms of how it affects our ability to get into P&T committees and the utilization of the product; and we definitely view six quarters, beginning January 1st, as a chance to, in fact, match and surpass that same uptake curve for Exparel. I think we're beginning to see signs of that already when it comes to significant increases in utilization just in the second half of February. And so, we're very excited, looking forward to being able to show the commercial value of ZYNRELEF for the remainder of this year and going forward.

John Poyhonen

executive
#22

Serge, I believe there was one more thing you asked about, and that was what figure ought to be applied when building a model, more or less net sales for each unit. So when you take into account how the SKUs are split between 400 and 200, and then factor in the gross-to-debt discount, Serge, using roughly $200 per unit would be a fairly solid figure to apply for modeling purposes.

Kelly Shi

analyst
#23

First off, I'd like to know whether you perceive any danger that CMS might not award ZYNRELEF pass-through status on April 1st, which would help with HOPD adoption. I've got a few additional questions too, thanks.

Barry Quart

executive
#24

Of course. Given the broader label, nothing suggests to us that more holdups in getting the green light are likely; we haven't heard of any. According to CMS, they already possess all the materials they require from our side. So at this point we're simply awaiting word. Then again, it's the government, isn't it?

Kelly Shi

analyst
#25

Got it. There are a few more things I'd like to ask about how ZYNRELEF is growing. First, I believe someone just brought up the fact that demand rose 47% in February compared with January. What I want to know is whether you saw a comparable rise in demand from last December to this January. My apologies if that was already covered. Second, when it comes to accounts that place a unique order versus those that order again, are you seeing the same degree of growth over time?

Barry Quart

executive
#26

Thank you, Kelly. I'll handle the first one, which is that no, things were pretty much flat from December into January; that period fell squarely in the middle of the Omicron surge, and we know firsthand that a great many surgeries got pushed back, since even when a hospital didn't have to cut back on surgeries, in certain cases half of the patients booked for an operation wound up testing positive for COVID when they arrived a day or two beforehand, or some staff members tested positive and those operations had to be delayed. So January stayed flat, and then once the COVID surge began to fade as we moved into February, surgeries started to rebound and utilization of ZYNRELEF went up quite nicely. John, would you like to handle the second one?

John Poyhonen

executive
#27

Yes. Looking at it through the lens of repeat orders, when Q3 wrapped up — that was our initial quarter of launch — the reorder rate stood at 50%, and it climbed to 73% across the fourth quarter, which was our second quarter of launch. Our expectation is that this figure will keep rising as time goes on. Since you are constantly bringing new accounts on board among those placing orders, reaching 100% is going to be difficult; however, as time passes, we anticipate that rate will carry on climbing. It certainly won't be at that same percentage, given there is less percentage left to work with, but we believe we'll keep seeing solid growth there as well, Kelly.

Barry Quart

executive
#28

Thanks. Appreciate everyone for being on today's call once more. We feel genuinely good about how things went this quarter, and we're eager to continue sharing updates with all of you.

Operator

operator
#29

Everyone, that brings us to the end of this call. We appreciate all of you joining. You're free to hang up now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Heron Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

For developers and AI pipelines

Programmatic access to Heron Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Heron Therapeutics, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.